From the Guidelines
Wegovy (semaglutide) is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as well as in pregnant or breastfeeding women, and those with a history of serious allergic reactions to semaglutide or any components of the medication. When considering the use of Wegovy, it is essential to be aware of the potential contraindications and precautions to ensure safe and effective treatment. Some key points to consider include:
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 1
- Pregnancy or breastfeeding, as the effects of semaglutide on fetal development and infants are not well established 1
- History of serious allergic reactions to semaglutide or any components of the medication 1
- History of pancreatitis, as GLP-1 receptor agonists have been associated with pancreatitis 1
- Severe gastrointestinal disease, including gastroparesis, as semaglutide slows gastric emptying 1
- Severe kidney disease or dialysis, as dose adjustments may be necessary 1 It is crucial to discuss all current medications with your healthcare provider before starting treatment with Wegovy to avoid potential drug interactions 1. By carefully evaluating these factors and considering the potential benefits and risks of treatment, healthcare providers can make informed decisions about the use of Wegovy in their patients.
From the FDA Drug Label
OZEMPIC is contraindicated in patients with: • A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)]. • Known hypersensitivity to semaglutide or to any of the product components [see Warnings and Precautions (5.7)].
The contraindications with Wegovy (semaglutide) are:
- A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to semaglutide or to any of the product components 2
From the Research
Contradication with Wegovy
- Wegovy, also known as semaglutide, is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used for the treatment of type 2 diabetes and weight management 3, 4.
- The use of semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, due to the increased risk of thyroid C-cell hyperplasia and C-cell tumors 3, 5, 6.
- Semaglutide has also been associated with other adverse effects, such as acute pancreatitis, anesthetic risks, acute kidney injury, and diabetic retinopathy 4.
- Patients with a history of pancreatitis should not use semaglutide, and it is not recommended for patients with suspected or confirmed pancreatitis 3.
- Semaglutide is not indicated for the treatment of type 1 diabetes, and its use in patients with a history of thyroidectomy requires careful monitoring of thyroid hormone levels 7.
Special Considerations
- When initiating semaglutide, gradual dose escalation is recommended to minimize the risk of gastrointestinal adverse events 3.
- Patients should be instructed to swallow the tablet with a small amount of water on an empty stomach, and to wait at least 30 minutes before eating, drinking, or taking other oral medications 3.
- The potential impact of semaglutide on concomitant medications, such as those used in diabetes treatment or anti-psychotics, should be considered 4.